[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544733":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":201,"collaborators":19,"id":203,"slug":204,"hasResults":205,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":209,"eligibilityCriteria":210,"healthyVolunteers":205,"sex":211,"minAge":212,"maxAge":19,"enrollmentInfo":213,"targetDuration":19,"studyType":216,"phases":217,"briefSummary":219,"conditions":220,"keywords":223,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},{"fullName":5,"class":6},"University Hospital, Brest","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with PE who have been treated with anticoagulant therapy for 3 to 6 uninterrupted months","EXPERIMENTAL","Patients who experienced an objectively proven PE who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.",[13],"Other: Ventilation\u002FPerfusion Single Photon Emission Computed Tomography (V\u002FQ SPECT\u002FCT)",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"Ventilation\u002FPerfusion Single Photon Emission Computed Tomography (V\u002FQ SPECT\u002FCT)","All patients will undergo a V\u002FQ SPECT\u002FCT scan at inclusion.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Pierre-Yves LE ROUX, Pr","CONTACT","+33298223327","pierre-yves.leroux@chu-brest.fr",[27,45,55,69,83,97,106,120,134,148,162,176,187],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":31,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"CHU Amiens","RECRUITING","Amiens","France","80054","FR",{"type":35,"coordinates":36},"Point",[37,38],2.3,49.9,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":19,"email":44},"Marie-Antoinette SEVESTRE, Pr","+33322087306","sevestre.marie-antoinette@chu-amiens.fr",{"facility":46,"status":47,"city":48,"state":31,"zip":49,"country":31,"countryCode":33,"cosmosGeoPoint":50,"geoPoint":54,"contacts":19},"CHU Angers","ACTIVE_NOT_RECRUITING","Angers","49933",{"type":35,"coordinates":51},[52,53],-0.55202,47.47156,{"lat":53,"lon":52},{"facility":56,"status":29,"city":57,"state":31,"zip":58,"country":31,"countryCode":33,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"CHU Brest","Brest","29609",{"type":35,"coordinates":60},[61,62],-4.48628,48.39029,{"lat":62,"lon":61},[65,66],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"name":67,"role":68,"phone":19,"phoneExt":19,"email":19},"Francis COUTURAUD, Pr","PRINCIPAL_INVESTIGATOR",{"facility":70,"status":29,"city":71,"state":31,"zip":72,"country":31,"countryCode":33,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Hôpital Louis MourierAP-HP","Colombes","92700",{"type":35,"coordinates":74},[75,76],2.25404,48.91882,{"lat":76,"lon":75},[79],{"name":80,"role":23,"phone":81,"phoneExt":19,"email":82},"Isabelle MAHE, Pr","+33147606490","isabelle.mahe@lmr.aphp.fr",{"facility":84,"status":29,"city":85,"state":31,"zip":86,"country":31,"countryCode":33,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"CHD Vendée - La Roche sur Yon","La Roche-sur-Yon","85925",{"type":35,"coordinates":88},[89,90],-1.42757,46.66974,{"lat":90,"lon":89},[93],{"name":94,"role":23,"phone":95,"phoneExt":19,"email":96},"Jean-Manuel KUBINA, Dr","+33251446301","jean-manuel.kubina@ght85.fr",{"facility":98,"status":47,"city":99,"state":31,"zip":100,"country":31,"countryCode":33,"cosmosGeoPoint":101,"geoPoint":105,"contacts":19},"Kremlin-Bicêtre AP-HP","Le Kremlin-Bicêtre","94270",{"type":35,"coordinates":102},[103,104],2.36073,48.81471,{"lat":104,"lon":103},{"facility":107,"status":29,"city":108,"state":31,"zip":109,"country":31,"countryCode":33,"cosmosGeoPoint":110,"geoPoint":114,"contacts":115},"CH Les Sables d'Olonne","Les Sables-d'Olonne","85340",{"type":35,"coordinates":111},[112,113],-1.7847,46.49687,{"lat":113,"lon":112},[116],{"name":117,"role":23,"phone":118,"phoneExt":19,"email":119},"Nicolas BREBION","+33251218824","nicolas.brebion@ght85.fr",{"facility":121,"status":29,"city":122,"state":31,"zip":123,"country":31,"countryCode":33,"cosmosGeoPoint":124,"geoPoint":128,"contacts":129},"Hegp Ap-Hp","Paris","75015",{"type":35,"coordinates":125},[126,127],2.3488,48.85341,{"lat":127,"lon":126},[130],{"name":131,"role":23,"phone":132,"phoneExt":19,"email":133},"Olivier Sanchez, Pr","+33165093487","olivier.sanchez@aphp.fr",{"facility":135,"status":29,"city":136,"state":31,"zip":137,"country":31,"countryCode":33,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"CH Quimper","Quimper","29000",{"type":35,"coordinates":139},[140,141],-4.09795,47.99597,{"lat":141,"lon":140},[144],{"name":145,"role":23,"phone":146,"phoneExt":19,"email":147},"Charles ORIONE, Dr","+33298526096","charles.orione@ch-cornouaille.fr",{"facility":149,"status":29,"city":150,"state":31,"zip":151,"country":31,"countryCode":33,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"CHU St-Etienne","Saint-Etienne","42055",{"type":35,"coordinates":153},[154,155],4.39,45.43389,{"lat":155,"lon":154},[158],{"name":159,"role":23,"phone":160,"phoneExt":19,"email":161},"Laurent BERTOLETTI, Pr","+33477127770","laurent.bertoletti@chu-st-etienne.fr",{"facility":163,"status":29,"city":164,"state":31,"zip":165,"country":31,"countryCode":33,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"CHIC Toulon","Toulon","83056",{"type":35,"coordinates":167},[168,169],5.92836,43.12442,{"lat":169,"lon":168},[172],{"name":173,"role":23,"phone":174,"phoneExt":19,"email":175},"Jean-Noël POGGI, Dr","+33494145787","jean-noel.poggi@ch-toulon.fr",{"facility":177,"status":29,"city":164,"state":31,"zip":178,"country":31,"countryCode":33,"cosmosGeoPoint":179,"geoPoint":181,"contacts":182},"HIA Toulon","83800",{"type":35,"coordinates":180},[168,169],{"lat":169,"lon":168},[183],{"name":184,"role":23,"phone":185,"phoneExt":19,"email":186},"Antoine-Raphaël BRONSTEIN, Dr","+33483162553","antoine-raphael.bronstein@intradef.gouv.fr",{"facility":188,"status":29,"city":189,"state":31,"zip":190,"country":31,"countryCode":33,"cosmosGeoPoint":191,"geoPoint":195,"contacts":196},"CHU Toulouse","Toulouse","31059",{"type":35,"coordinates":192},[193,194],1.44367,43.60426,{"lat":194,"lon":193},[197],{"name":198,"role":23,"phone":199,"phoneExt":19,"email":200},"Alessandra BURA-RIVIERE, Pr","+33561322438","bura-riviere.a@chu-toulouse.fr",{"type":202,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100544733","residual-pulmonary-vascular-obstruction-index-computed-with-ventilationperfusion-spectct-imaging-to-predict-the-risk-of-venous-thromboembolism-recurrence-in-patients-with-pulmonary-embolism-pronospect-100544733",false,"NCT06372730","Residual Pulmonary Vascular Obstruction Index Computed With Ventilation\u002FPerfusion SPECT\u002FCT Imaging to Predict the Risk of Venous Thromboembolism Recurrence in Patients With Pulmonary Embolism (PRONOSPECT)","Residual Pulmonary Vascular Obstruction (RPVO) Index Computed With Ventilation\u002FPerfusion SPECT\u002FCT Imaging to Predict the Risk of Venous Thromboembolism (VTE) Recurrence in Patients With Pulmonary Embolism (PE)","PRONOSPECT","Inclusion Criteria:\n\n* Patients ≥ 18 years,\n* who experienced an objectively proven PE,\n* who have been treated initially with anticoagulant therapy for 3 to 6 uninterrupted months (180 - 210 days) and for whom anticoagulation will not be prolonged.\n\nExclusion Criteria:\n\n* Unwilling or unable to give written informed consent (protected adults, under tutorship or curatorship)\n* Patients deprived of their liberty by a judicial or administrative decision, patients undergoing psychiatric care by virtue of Articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and patients admitted to a health or social establishment for purposes other than research\n* No Social security affiliation\n* Isolated DVT\n* Pregnant women and parturients\n* Other indication for anticoagulant therapy (e.g. atrial fibrillation, mechanic valve)\n* Life expectancy \\\u003C 6 months\n* Any patients for whom there is a strong indication to treat longer than 6 months:\n\n  * PE provoked by a major persistent factor (e.g. cancer)\n  * Recurrent unprovoked PE\n\nPE provoked by a major transient risk factor (e.g. surgery with general anesthesia for greater than 30 min, confined to bed in hospital for at least 3 days with an acute illness, cesarean section)\n\nAND none of the following persistent factors :\n\n* BMI ≥ 30\n* Chronic respiratory disease\n* Chronic inflammatory disease (e.g., ulcerative colitis, rheumatoid arthritis, etc.)\n* Hepatocellular insufficiency\n* Renal insufficiency with creatinine clearance \\\u003C 60 mL\u002Fmin\n* Chronic or persistent immobilization","ALL","18 Years",{"count":214,"type":215},665,"ESTIMATED","INTERVENTIONAL",[218],"NA","Major risk after pulmonary embolism (PE) is recurrence, fatal in 10% of patients. Patients with PE can be stratified in 3 groups according to the risk of recurrence : very low risk, high risk or Intermediate risk. Little is known about this last group.\n\nAnticoagulation is efficient to prevent recurrence but is currently not recommended for patient with an intermediate risk of recurrence.\n\nIdentifying risk factors of recurrent PE remains a major issue to identify sub-groups of patients who would require lifelong anticoagulation.\n\nIn 30-40% of cases, PE patients develop residual pulmonary vascular obstruction (RPVO), which has been found to be associated with an increased recurrence risk. This last observation was mostly reported in patients with unprovoked PE (patients with high risk of recurrence) and RPVO was measured using conventional planar lung scan.\n\nIn patients with an intermediate risk of recurrence, the impact of RPVO has been much less studied. In addition, the definition of RPVO was variable according to studies and correlation between RPVO burden and recurrence risk has not been clearly demonstrated. This might be explained by the inherent limitation of RPVO quantification using conventional planar imaging, which is only based on a visual estimation on 2-dimensional images.\n\nVentilation\u002FPerfusion Single Photon Emission Computed Tomography (V\u002FQ SPECT\u002FCT) is a new method of scintigraphic image acquisition that offers the advantage of 3-dimensional imaging, enabling more accurate and reproducible quantification of RPVO.\n\nThe main hypothesis of this study is that in patients with PE at intermediate risk of recurrence, RPVO computed with V\u002FQ SPECT\u002FCT imaging may be an important predictor of recurrence.",[221,222],"Pulmonary Embolism","Venous Thromboembolism",[224],"venous thromboembolism recurrence","2026-06-12",{"date":227,"type":228},"2026-06-15","ACTUAL",{"date":230,"type":228},"2024-06-11",{"date":232,"type":215},"2029-03",{"name":5,"class":6},13]